Oct-Dec, 2011 - Indian Journal of Pharmacy Practice

More documents

Recommendations

Info

Dinesh KU - Evaluation of the Impact of a Pharmaceutical Care Program for Diabetes Patients in Nepal: A Preliminary StudyAlcohol intakeEveryday 1 3 0Occasional 0 1 1Former 3 3 2Never 6 4 7Smoking StatusEveryday 0 1 0Occasional 0 1 1Former 6 3 1Never 4 6 8Monthly Income (Nrs.)0-10000 6 7 410001-20000 2 1 420001-30000 1 2 130001-40000 0 1 140001-50000 1 0 0Family typeJoint 7 6 7Separate 3 5 3Family history of diseaseFather 0 1 1Mother 0 0 1Both 0 0 0BMI= Body Mass Index, NRs = Nepali rupeesDiabetic history: Two (6.45%) had their father alone while 1(3.22%) had their mother alone suffered from diabetes. Thefamily history of 28 (90.32%) patients was unknown.Therapeutic category of medication prescribed:Altogether 75 drugs were prescribed in the study population.Antidiabetics were the commonest class of drugs prescribedaccounting for 36 (48%) of the total drugs followed bycardiovascular drugs 22 (29.33%). Other medicines were17(22.66%) in number which included diuretics, vitaminsupplements, proton pump inhibitors and antimicrobials.Utilization of antidiabetics in study population: Out of 36antidiabetics prescribed, 17 (47.22%) drugs were foundcommonly prescribed from the class of biguanides followedby sulfonylureas 12 (33.33%), Insulin preparation 5(13.88%), Thiazolidinedione group of drugs 1(2.77%) andalpha glucosidase inhibitors 1(2.77%). Insulin was used in 2(12.5%) patients of CG, 1(14.28%) of TG-1 and 2(15.38%) ofTG-2 patients. Biguanides was used in 7 (43.75%) patients ofCG, 4 (57.14%) of TG-1 and 6(46.15%) of TG-2 patients.Sulfonylurea class of drugs was used in 6 (37.5%) patients ofCG followed by 2 (28.57%) of TG-1 and 4 (30.76%) of TG-2patients. Only one patient of TG-2 group and one patient ofCG were prescribed thiazolidinedione and alpha glucosidaseinhibitor class of drugs , respectively.Comparison of blood glucose pattern: All three grouppatients were evaluated for their blood sugar level at baselineand after intervention and median interquartile range wasobtained and compared for any significant effect. It was foundthat the patients of TG-2 shown the significant improvementin terms of their blood glucose level [FBS (P value= 0.008)PPBG (P value= 0.008)] as compared to TG-1 [FBS (P value=0.025) PPBG (P value= 0.050)].This significant improvementin test group-2 patients might be due to demonstration ofdiabetic kit to TG-2 subjects which made them more clearabout the fate of fatty and sugary substances once they areconsumed in the body. The median for all three groups arementioned in Table 2.Response to knowledge questions: The response of thepatients regarding the knowledge questions at baseline andafter intervention was done. The number of patientsresponding correctly to the knowledge questions ismentioned in Table 3.Indian Journal of Pharmacy Practice Volume 4 Issue 4 Oct - Dec, 2011 54
Dinesh KU - Evaluation of the Impact of a Pharmaceutical Care Program for Diabetes Patients in Nepal: A Preliminary StudyGroupsCG(n=10)TG-1(n=11)TG-2(n=10)stBaseline (1 day of visit to thehospital) Median(interquartile range)RBSFBSPPBS339 (204-438)208 (148-287)348 (322-386)GroupsCG(n=8)Intervention (2 months from the dateof enrollment)Median (interquartile range)-P value90.5 (79-103)CG pre FBS Vs CG postFBS 0.012180 (138-211) CG pre PPBS Vs CG postPPBS 0.012HbA1c - - -RBS397 (209-423)--FBS135 (122-260)98.5 (84-108)TG-1 pre FBS Vs postTG-1FBS 0.025PPBS 249 (155-379) (n=8)130 (103-140) TG-1 pre PPBS Vs postPPBS 0.050HbA1c - - -RBSTable 2: Comparison of blood glucose level of all three groups360 (210-388)FBS244 (159-360)104 (93-114)TG-2 pre FBS Vs postTG-2FBS 0.008PPBS 379 (235-416) (n=9)118 (104-188) TG-2 pre PPBS Vs postPPBS 0.008HbA1c 9.2 (8.8-10) - ----Table 3: Number of patient responding correctly to the Knowledge questionsControl group Test group-1 Test group-2Questions Baseline 2 months Baseline 2 months Baseline 2 months(n=10) (n=8) (n=11) (n=8) (n=10) (n=9)n (%) n (%) n (%) n (%) n (%) n (%)1 2 (20) 6 (75) 5 (45.455) 8 (100) 8 (80) 9 (100)2 0 0 1 (9.09) 1 (12.5) 1 (10) 2 (22.22)3 0 0 2 (18.18) 2 (25) 1 (10) 7 (77.78)4 1 (10) 3 (37.5) 4 (36.36) 8 (100) 3 (30) 8 (88.89)5 3 (30) 5 (62.5) 6 (54.55) 8 (100) 7 (70) 9 (100)6 0 2 (25) 4 (36.36) 8 (100) 6 (60) 7 (77.78)7 5 (50) 7 (87.5) 9 (81.82) 8 (100) 6 (60) 9 (100)8 2 (20) 5 (62.5) 8 (72.73) 8 (100) 8 (80) 9 (100)9 2 (20) 3 (37.5) 7 (63.64) 8 (100) 8 (80) 8 (88.89)10 0 0 1 (9.09) 2 (25) 2 (20) 1 (11.11)11 1 (10) 3 (37.5) 4 (36.36) 8 (100) 7 (70) 8 (88.89)12 2 (20) 0 2 (18.18) 4 (50) 4 (40) 7 (77.78)13 0 2 (25) 4 (36.36) 7 (87.5) 4 (40) 6 (66.67)14 4 (40) 4 (50) 6 (54.55) 8 (100) 9 (90) 8 (88.89)15 7 (70) 7 (87.5) 8 (72.73) 8 (100) 10 (100) 9 (100)16 3 (30) 2 (25) 3 (27.27) 7 (87.5) 5 (50) 8 (88.89)17 1 (10) 1 (12.5) 2 (18.18) 7 (87.5) 5 (50) 5 (55.56)18 0 2 (25) 4 (36.36) 8 (100) 6 (50) 8 (88.89)Indian Journal of Pharmacy Practice Volume 4 Issue 4 Oct - Dec, 2011 55
Page 1 and 2:
Indian Journal of Pharmacy Practice
Page 3 and 4:
Dear ReadersIndian Journal of Pharm
Page 5 and 6: Daxesh M P - Combating Antimicrobia
Page 11 and 12: Indian Journal of Pharmacy Practice
Page 13 and 14: J. Chang - India's Progress towards
Page 15 and 16: J. Chang - India's Progress towards
Page 17 and 18: Shobha C - Poison Information Cente
Page 25 and 26: Anantha Naik N -Health Related Qual
Page 33 and 34: Amrita P - Scenario of Pharmacovigi
Page 42 and 43: Satyanarayana V - Evaluation of the
Page 52 and 53: Dinesh KU - Evaluation of the Impac
Page 66 and 67: Pratham R - A Retrospective Study o
Page 70 and 71: Anoop P -Impact of Clinical Pharmac
Page 76 and 77: Singh B -Respiratory Tract Problems
Page 78 and 79: Singh B -Respiratory Tract Problems
Page 80 and 81: Mihir Y.P - Study of Prescribing Pa
Page 84 and 85: Ramanath K.V -Evaluation of the Imp
Page 86 and 87: Ramanath K.V -Evaluation of the Imp
Page 88 and 89: Instructions to AuthorsIntroduction
Page 90: Instructions to AuthorsElectronic j
show all

Oct-Dec, 2011 - Indian Journal of Pharmacy Practice

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?